News

  • ACLA Comments on CLIA proposed rule on Proficiency Testing

    April 11, 2019
    ...
  • ACLA Elects 2019-2020 Board of Directors

    March 28, 2019
    Washington, D.C. – The American Clinical Laboratory Association (ACLA) today announced the election of its new Board of Directors for 2019-2020. Douglas M. VanOort, Chairman and CEO of NeoGenomics Laboratories will take on a new leadership role as ACLA Board Chair, replacing Dr. Curtis Hanson of Mayo Clinic Laboratories. Jerry Hussong, CEO of Sonic Healthcare USA was elected Vice Chair and John Kolozsvary, CEOContinue Reading »...
  • ACLA Files Reply Brief Ahead of Oral Arguments in ACLA v. Azar Appeal

    March 18, 2019
    HHS’ data collection process under PAMA disregards Congressional intent, jeopardizing lab access for millions of seniors Washington, D.C. – The American Clinical Laboratory Association (ACLA) filed a reply brief today ahead of oral arguments in the ACLA v. Azar appeal which has been scheduled for April 23, 2019. The brief reinforces ACLA’s argument that the U.S. Department of Health and Human Services (HHS) failedContinue Reading »...
  • With all eyes on cancer moonshot, labs continue to prove value

    March 12, 2019
    In 2019, an estimated 1.7 million new cancer cases will be diagnosed in the U.S., according to the American Cancer Society. As patients and their families across the country grapple with how to manage and overcome this painful disease, clinical labs are busy developing and providing innovative methods to identify, diagnose and monitor cancer. From early detection and evaluating the best course of treatment,Continue Reading »...
  • GAO acknowledges recent report projected lab spending based on hypothetical framework

    February 28, 2019
    The U.S. Government Accountability Office (GAO), often referred to as the “congressional watchdog,” is supposed to examine how taxpayer dollars are spent, and then provide Congress and federal agencies with objective, reliable information to help save money and work efficiently. And yet, following growing pushback to a recent report on laboratory billing practices in the Medicare program, James Cosgrove, GAO health care director andContinue Reading »...
  • ACLA Statement on New Genetic Testing Guidelines for Hereditary Breast Cancer

    February 27, 2019
    New guidelines issued by the American Society of Breast Surgeons call for genetic testing to be available for all breast cancer patients Washington, D.C. – In response to the American Society of Breast Surgeons’ (ASBrS) recently released guidelines on genetic testing for hereditary breast cancer, ACLA President Julie Khani issued the following statement: “Our ability to pinpoint the start of breast cancer at itsContinue Reading »...
  • Leading Health Groups Challenge GAO’s Flawed Report on Medicare Lab Billing

    February 25, 2019
    Washington, D.C. – In response to broad and misleading claims in a recent Government Accountability Office (GAO) report, leading clinical laboratory, diagnostic and provider organizations challenged the agency on a number of recommendations that could lead to disruption to seniors’ access to critical laboratory diagnostics. The joint letter from AdvaMedDx, American Clinical Laboratory Association (ACLA), College of American Pathologists (CAP), National Independent Laboratory Association (NILA)Continue Reading »...
  • Clinical laboratory diagnostics play key role in understanding heart health

    February 22, 2019
    Through innovation and advances in science, the health system has made significant progress in identifying and treating cardiovascular disease – the most significant development being the reduction in heart attacks and strokes. In fact, from 1980 to 2014, the number of Americans dying from cardiovascular disease dropped in half. While we now know more than ever before about the risk factors associated with heartContinue Reading »...
  • Letter from Industry Stakeholders in Response to GAO Report on PAMA

    February 21, 2019
    ...
  • Leading a new generation of personalized medicine, LDTs must be key consideration in diagnostic reform

    February 13, 2019
    Lab developed tests (LDTs) are essential to health care delivery and the broader health system, helping pave the way for a new era of personalized medicine and making it possible to achieve national health goals like the Cancer Moonshot. These vital tests are developed and performed by individual laboratories, providing reliable, early diagnosis for many rare and increasingly complex conditions. In many cases, LDTsContinue Reading »...